|
Synonyms: ALTUVIIIO® | Altuvoct® | BIVV-001 | BIVV001 | Fc-VWF-XTEN
efanesoctocog alfa is an approved drug (FDA (2023), EMA (2024))
Compound class:
Peptide
Comment: Efanesoctocog alfa (BIVV-001) is a recombinant protein that fuses factor VIII (FVIII) to a human IgG1 Fc domain. It was designed as a long-acting FVIII replacement therapy [4]. Pharmacodynamic effects of efanesoctocog alfa (clot formation) are identical to those elicited by recombinant FVIII [1].
|
| Bioactivity Comments |
| Efanesoctocog alfa pharmacokinetics were reported in late 2023 [3]. |
